fam126a Antibody

What is FAM126A and why is it significant for research?

FAM126A (also known as Hyccin) is a protein that regulates the synthesis of phosphatidylinositol 4-phosphate (PI4P), which is an important determinant of plasma membrane identity . It functions as an intrinsic component of the plasma membrane phosphatidylinositol 4-kinase complex that comprises PI4KIIIα and its adaptors TTC7 and EFR3 . Its significance stems from its role in membrane biology and its implications in diseases. Notably, mutations in FAM126A have been associated with hypomyelination and congenital cataract (HCC), a leukodystrophy condition . More recently, studies have shown that loss of FAM126A expression in colorectal cancer can create a dependency on FAM126B, suggesting potential therapeutic vulnerabilities .

When designing experiments to study FAM126A, researchers should consider that it exists in two splice forms (58 kD and 47 kD), with the 58 kD form predominant in mammalian brain tissue . The protein has a structured N-terminal portion (residues 1-289) common to both splice forms and a less conserved C-terminal tail (residues 290-521) .

What are the recommended applications for FAM126A antibodies?

Based on available commercial products and research protocols, FAM126A antibodies are primarily validated for Western blot (WB) applications . When using these antibodies, researchers should follow recommended dilution ratios, typically in the range of 1:500-2000 for Western blot applications .

For optimal results in Western blot experiments, researchers should load approximately 40 μg of protein lysate and use appropriate primary antibody dilutions (around 1:300 has been validated with mouse heart lysate) . When interpreting results, expect to observe a band of approximately 58 kD, which corresponds to the major splice form of FAM126A . Secondary antibody selection should be complementary to the primary antibody's host species, with infrared or chemiluminescent detection systems providing consistent results.

What controls should be included when working with FAM126A antibodies?

When conducting experiments with FAM126A antibodies, several controls are essential to ensure result validity:

Positive controls should include tissues or cell lines known to express FAM126A, such as brain tissue or certain colorectal cancer cell lines like DLD1 and HCT116, which have been demonstrated to express high levels of FAM126A protein . Negative controls could utilize tissues or cell lines with low or no FAM126A expression, such as RKO and SW48 colorectal cancer cell lines that have been shown to have undetectable FAM126A protein levels by Western blotting .

For knockout validation, samples from FAM126A knockout mice or cells treated with FAM126A-targeting sgRNAs can serve as specificity controls, as they should not display the characteristic immunoreactive bands at 58 kD and 47 kD . When available, competing peptide controls using the synthetic peptide derived from human hyccin 1-100/521 region (which is used as an immunogen for antibody production) can further confirm specificity .

How should FAM126A antibodies be stored and handled?

For optimal preservation of antibody activity and specificity, store FAM126A antibodies at -20°C for long-term storage (up to one year) . Avoid repeated freeze/thaw cycles as this can degrade antibody quality and reduce specificity. The lyophilized form of the antibody demonstrates greater stability, remaining stable at room temperature for at least one month and for more than a year when kept at -20°C .

When working with reconstituted antibodies, store them at 2-4°C for short-term use (up to two weeks) in sterile pH 7.4 0.01M PBS or appropriate antibody diluent . Commercial FAM126A antibodies are typically formulated in liquid 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300, and 50% Glycerol for stability . When diluting the antibody for experimental applications, use fresh, cold buffer and handle the antibody with clean pipettes to prevent contamination.

How can I detect differential expression of FAM126A splice variants?

The detection of FAM126A splice variants requires experimental approaches that can distinguish between the 58 kD and 47 kD isoforms. Western blot analysis is the primary method for this purpose, using antibodies that can recognize regions common to both splice forms . To optimize detection of both variants, use protein extraction protocols that effectively preserve membrane-associated proteins, such as RIPA buffer supplemented with protease inhibitors.

For quantitative comparison of splice variants across tissue types or disease states, develop a consistent loading control strategy and employ densitometric analysis. In brain tissue, expect predominance of the 58 kD isoform , while the distribution in other tissues might vary. If studying tissues where both variants might be expressed, consider employing gradient gels (8-12% polyacrylamide) to achieve better separation of the two isoforms.

For validation at the transcript level, design PCR primers that can distinguish between the splice variants. This complementary approach can confirm whether differential expression occurs at the transcriptional or post-transcriptional level. When interpreting results indicating altered splice variant ratios, consider developmental, tissue-specific, or disease-related factors that might influence alternative splicing regulation.

What strategies can address potential cross-reactivity with FAM126B?

Given the identified redundant functions between FAM126A and FAM126B in the PI4KIIIα complex , cross-reactivity is a critical concern for researchers. To address this issue, first verify the specificity of your FAM126A antibody by testing it against recombinant FAM126A and FAM126B proteins if available. If cross-reactivity is observed, implement a differential detection strategy.

For definitive differentiation, consider employing genetic approaches such as using cell lines with CRISPR-Cas9 knockout of either FAM126A or FAM126B as controls . In these systems, any remaining signal after knockout can be attributed to potential cross-reactivity. Testing antibodies in paired cell lines with differential expression of FAM126A (such as DLD1/HCT116 versus RKO/SW48) can provide further validation of specificity .

For advanced studies requiring absolute specificity, consider using epitope-tagged versions of FAM126A and FAM126B in experimental systems . This approach allows detection with antibodies against the epitope tag rather than the proteins themselves, eliminating cross-reactivity concerns. When interpreting results from systems where both proteins are expressed, acknowledge the potential limitations of antibody-based detection and supplement with orthogonal methods.

How can I investigate the interaction between FAM126A and the PI4KIIIα complex?

Investigating the interactions between FAM126A and other components of the PI4KIIIα complex requires multiple complementary approaches. Co-immunoprecipitation (co-IP) experiments represent a foundational method, using GFP-tagged FAM126A or TTC7B to pull down associated proteins, followed by immunoblotting for complex components . For more physiologically relevant conditions, consider performing co-IP of endogenous proteins using antibodies against FAM126A, PI4KIIIα, TTC7, or EFR3.

For studying the direct interaction between FAM126A-N and TTC7B, recombinant protein expression in E. coli followed by size-exclusion chromatography analysis can confirm complex formation . To analyze the architecture of larger multi-protein complexes, implement sequential co-IP approaches or conduct multi-angle light scattering experiments.

To visualize these interactions in cellular contexts, fluorescence microscopy approaches using differentially tagged proteins can reveal co-localization patterns at the plasma membrane . For quantitative assessment of protein-protein interactions, techniques such as Förster resonance energy transfer (FRET), proximity ligation assay (PLA), or bimolecular fluorescence complementation (BiFC) provide valuable insights into the spatial relationship between complex components.

When investigating how mutations or deletions affect complex assembly, compare wild-type interactions with those of variant proteins, particularly focusing on the structured N-terminal portion of FAM126A (residues 1-289) that mediates key interactions .

What methods can determine if FAM126A loss causes FAM126B dependency in my experimental model?

To establish whether FAM126A loss creates FAM126B dependency in your experimental model, implement a systematic approach combining genetic manipulation with functional assays. First, characterize baseline expression of both FAM126A and FAM126B in your model system using Western blot and quantitative RT-PCR analyses . This establishes whether your system has a FAM126A-high or FAM126A-low baseline state.

Then conduct genetic depletion experiments using CRISPR-Cas9 or RNAi approaches targeting FAM126B in both FAM126A-expressing and FAM126A-deficient contexts . To create FAM126A-deficient models from FAM126A-high systems, either knockout FAM126A using CRISPR-Cas9 or use models with naturally low FAM126A expression . Conversely, to test recovery from dependency, introduce exogenous FAM126A expression in FAM126A-low systems .

Measure cellular fitness using competitive growth assays where cells with FAM126B depletion are grown in competition with control cells . For assessing cell death mechanisms, analyze apoptotic markers such as cleaved PARP1 by Western blotting . To extend findings to in vivo contexts, consider xenograft experiments in nude mice with FAM126B-depleted cells, comparing tumor growth rates between FAM126A-high and FAM126A-low models .

For genome-wide assessment of genetic dependencies associated with FAM126A status, implement CRISPR-Cas9 screens comparing FAM126A-high versus FAM126A-low states, which can reveal whether FAM126B emerges as a top dependency as expected .

How can FAM126A protein levels be accurately quantified across different sample types?

Accurate quantification of FAM126A protein levels across different sample types requires rigorous standardization of protein extraction, detection, and normalization methods. For consistent protein extraction, optimize lysis buffers based on the cellular localization of FAM126A, considering that it functions as part of a membrane-associated complex . For tissues or cells with different compositions, validate equivalent protein extraction efficiency by comparing recovery of membrane and cytosolic markers.

When performing Western blot analysis, establish a linear detection range by running a dilution series of positive control samples . This calibration curve will ensure that signal quantification falls within the linear response range of your detection system. Select appropriate housekeeping proteins for normalization based on their stability across your experimental conditions, potentially including β-actin, GAPDH, or membrane-specific markers depending on the compartment being analyzed.

For absolute quantification, consider using recombinant FAM126A protein as a standard . When comparing protein levels across diverse sample types (e.g., different tissues or cell lines), implement normalization strategies that account for potential differences in cellular composition and protein extraction efficiency. When reporting quantitative differences, always include statistical analyses and clearly state the normalization approach used.

What promoter methylation analysis methods can detect FAM126A silencing in cancer?

Given that promoter hypermethylation correlates with loss of FAM126A expression in colorectal cancer cell lines and tumor samples , several methods can be employed to analyze this epigenetic modification. Bisulfite sequencing represents the gold standard approach, allowing single-nucleotide resolution mapping of methylated cytosines in the FAM126A promoter region. Design primers that flank CpG islands in the FAM126A promoter and sequence multiple clones to generate a comprehensive methylation profile.

For higher throughput analysis across multiple samples, methylation-specific PCR (MSP) can be employed with primer sets designed to distinguish between methylated and unmethylated versions of the FAM126A promoter. Alternatively, quantitative methylation-specific PCR provides more precise quantification of methylation levels. Pyrosequencing offers an intermediate approach, providing quantitative methylation data for multiple CpG sites with moderate throughput.

To establish the functional relationship between promoter methylation and gene expression, treat cells with DNA methylation inhibitors such as 5-aza-2'-deoxycytidine and measure resulting changes in FAM126A expression by qRT-PCR and Western blot . When analyzing clinical samples, correlate methylation patterns with FAM126A expression levels and clinicopathological features to establish potential prognostic significance.

For genome-wide context, consider integrating FAM126A methylation analysis with broader epigenetic profiling techniques such as reduced representation bisulfite sequencing (RRBS) or Illumina methylation arrays.

How should I design experiments to investigate the role of FAM126A in PI4P synthesis?

Investigating FAM126A's role in PI4P synthesis requires experimental approaches that can accurately measure phosphoinositide levels and track their dynamics. Begin with genetic manipulation of FAM126A, using CRISPR-Cas9 knockout or RNAi knockdown approaches, coupled with rescue experiments using wild-type or mutant FAM126A constructs . For acute depletion studies, consider implementing inducible degradation systems like the auxin-inducible degron system to rapidly eliminate FAM126A protein .

For direct assessment of PI4P levels, implement thin-layer chromatography or high-performance liquid chromatography analysis of extracted phospholipids labeled with radioactive phosphate. For spatial visualization of PI4P in cells, use PI4P-specific biosensors based on the PH domain of OSBP or the P4M domain of SidM, coupled with fluorescence microscopy . These approaches allow for the monitoring of PI4P at specific cellular membranes.

When examining the formation and function of the PI4KIIIα complex, complement biochemical interaction studies with functional assays of kinase activity using purified components . For cellular studies, employ systems with differential FAM126A expression, such as patient-derived fibroblasts from individuals with FAM126A mutations compared with control fibroblasts .

To connect PI4P synthesis defects with cellular phenotypes, monitor downstream processes dependent on proper PI4P levels, including membrane trafficking events, cell viability, and responses to specific cellular stresses.

How can I address weak or absent signal when using FAM126A antibodies?

When confronted with weak or absent signal in FAM126A detection experiments, implement a systematic troubleshooting approach. First, verify antibody quality by checking expiration date, storage conditions, and performing a dot blot with recombinant FAM126A protein if available . If the antibody appears functional, focus on sample preparation by ensuring adequate protein extraction, particularly since FAM126A functions in membrane-associated complexes, which may require specialized lysis conditions .

Consider that FAM126A expression is variable across tissues and cell lines, with some colorectal cancer cell lines like RKO and SW48 showing undetectable levels . When working with potentially low-expressing samples, increase protein loading (up to 60-80 μg) and optimize antibody concentration by testing a dilution series . Enhance signal detection by using high-sensitivity ECL substrates or fluorescent secondary antibodies with optimized imaging parameters.

If these approaches fail to generate signal, consider the possibility that your experimental model has silenced FAM126A expression, particularly in cancer cell lines where promoter hypermethylation can occur . To test this hypothesis, treat cells with DNA methylation inhibitors and reassess FAM126A expression. For persistent detection issues, consider targeting the 58 kD isoform, which is more abundantly expressed in most tissues compared to the 47 kD isoform .

How do I interpret conflicting results between FAM126A antibody detection and transcript measurements?

Discrepancies between protein detection using FAM126A antibodies and mRNA measurements require careful analysis of potential biological and technical factors. From a biological perspective, consider post-transcriptional regulation mechanisms that could affect protein abundance independently of transcript levels. These include alterations in translation efficiency, protein stability, or degradation pathways that might selectively affect FAM126A protein.

From a technical standpoint, verify the specificity of both detection methods. For antibody-based detection, confirm specificity using appropriate controls as previously described . For transcript measurements, validate primer specificity and efficiency, particularly when distinguishing between splice variants. When discrepancies persist despite technical validation, investigate potential biological explanations through time-course experiments that might reveal temporal disconnects between transcription and protein expression.

In cancer research contexts, consider that epigenetic modifications like promoter hypermethylation might create scenarios where transcriptional silencing occurs gradually or incompletely . Similarly, mutations affecting protein stability rather than expression could lead to reduced protein detection despite normal transcript levels. When reporting such discrepancies in research, present both protein and transcript data with appropriate controls and discuss potential biological mechanisms that might explain the observations.

What emerging methodologies might enhance FAM126A research?

Several emerging methodologies hold promise for advancing FAM126A research. Proximity labeling techniques like BioID or APEX2 fusion proteins could map the complete interactome of FAM126A beyond the known PI4KIIIα complex components . These approaches would identify proteins that transiently interact with FAM126A or associate with it in specific cellular contexts.

Cryo-electron microscopy represents a powerful approach for determining the complete structure of the PI4KIIIα complex with FAM126A at near-atomic resolution . This would build upon existing crystallographic data for the FAM126A-N/TTC7 heterodimer and provide insights into the complete complex architecture and mechanism.

CRISPR-based epigenome editing could enable targeted demethylation of the FAM126A promoter in cancer cells with silenced expression . This would provide a more precise tool than global demethylating agents for establishing the causal relationship between promoter methylation and gene silencing.

Optogenetic or chemogenetic tools for acutely controlling FAM126A localization or function would enable precise temporal control over its activity, facilitating the study of immediate consequences of FAM126A disruption. For translational applications, the development of proteolysis-targeting chimeras (PROTACs) targeting FAM126B could provide a therapeutic approach for colorectal cancers with FAM126A deficiency .

How might single-cell approaches advance understanding of FAM126A in heterogeneous tissues?

Single-cell approaches offer powerful tools for unraveling FAM126A biology in complex, heterogeneous tissues. Single-cell RNA sequencing (scRNA-seq) would reveal cell type-specific expression patterns of FAM126A and FAM126B across tissues, potentially identifying cellular populations with differential dependency relationships . This approach could be particularly valuable in tumor samples, where heterogeneity in FAM126A expression might create subpopulations with distinct therapeutic vulnerabilities.

Single-cell proteomics, while still developing as a technology, would enable quantification of FAM126A protein levels and post-translational modifications at the individual cell level. This could reveal population heterogeneity that might be masked in bulk analyses. Spatial transcriptomics and proteomics approaches would maintain tissue context while providing expression information, allowing correlation of FAM126A expression with specific microenvironmental features or spatial relationships to other cell types.

For functional studies, CRISPR screens at single-cell resolution could identify cell type-specific genetic interactions with FAM126A, potentially revealing context-dependent functions beyond its role in PI4P synthesis . When implementing these approaches, appropriate computational analyses will be essential for extracting meaningful biological insights from the resulting high-dimensional datasets.